Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Fountain Pharmaceuticals (FPHI) -- Ignore unavailable to you. Want to Upgrade?

To: r. peter Dale who wrote (59)	1/2/1998 5:16:00 PM
From: Courtney Willfore	Respond to of 78

Hey Peter...Happy N year Please confirm that I'm drift catching correctly: you're proposing that Fountain could package Ariad's plasmid constructs and/or binding proteins into their liposomes and then use a cream (whatever) to 'deliver' the drug to the skin. I understand you're not suggesting that Ariad get in the dermatology business but rather this may be a catalyst to show how the delivery system can work in vivo. I'm not quite sure how the in vitro data relates to this 'real life' scenario but the concept would seem to warrant serious consideration. The idea would seem to be mutually beneficial: Ariad may have an interesting proof of methodology approach and Fountain would have a drug delivery system. Neat. More later. CW